Breaking News Instant updates and real-time market news.

NVS

Novartis

$83.27

0.11 (0.13%)

05:36
07/18/17
07/18
05:36
07/18/17
05:36

Novartis backs FY17 revenue guidance of 'broadly in line with the prior year'

Novartis provided the following FY17 outlook: "We re-confirm our Group outlook as presented at the beginning of 2017. Group net sales in 2017 are expected to be broadly in line with the prior year, after absorbing the impact of generic competition, including the continued genericization of Gleevec/Glivec in the U.S. and Europe. From a divisional perspective, we expect net sales performance in 2017 to be as follows: Innovative Medicines: broadly in line with prior year, to a slight increase; Sandoz: broadly in line with prior year; Alcon: revised upward to low single digit growth. Group core operating income in 2017 is expected to be broadly in line with prior year to a low single digit decline. If mid-July exchange rates prevail for the remainder of 2017, the currency impact for the year would be negative 1 percentage point on net sales and negative 2 percentage points on core operating income."

  • 18

    Jul

NVS Novartis
$83.27

0.11 (0.13%)

07/14/17
LEER
07/14/17
NO CHANGE
Target $36
LEER
Outperform
Leerink sees significant optionality for AstraZeneca beyond MYSTIC trial
Leerink analyst Seamus Fernandez said he sees significant optionality for AstraZeneca (AZN) beyond the "mega-catalyst" of the MYSTIC trial in non-small cell lung cancer, as he believes several 2017 and 2018 readouts from underappreciated pipeline assets could lead to upside for the shares. If MYSTIC fails, Astra's "massive" SG&A spend gives it flexibility to mute the bottom-line impact. If it is successful, he believes potential acquirers such as Pfizer (PFE) or Novartis (NVS) could see "an attractive target to plunder," Fernandez tells investors. He keeps an Outperform rating and $36 price target on AstraZeneca ADRs.
07/13/17
SBSH
07/13/17
NO CHANGE
SBSH
Novartis vote bodes well for Kite and Juno, says at Citi
Citi analyst Robyn Karnauskas believes the FDA's unanimous vote in favor of Novartis' (NVS) CAR-T bodes well for Kite Pharma (KITE) and Juno Therapeutics (JUNO). Yesterday's panel meeting provides a preview of what Kite can expect ahead of its November 29 FDA action date, Karnauskas tells investors in a research note. She believes the expert commentary from the panel has "overarching implications" for Kite and Juno, both of which are developing CAR-T therapies for multiple indications.
07/12/17
RHCO
07/12/17
NO CHANGE
Target $108
RHCO
Buy
bluebird bio recent weakness unwarranted, says SunTrust
SunTrust analyst Edward Nash views the weakness in bluebird bio (BLUE) shares since the FDA briefing document on Novartis' (NVSR) CAR T product candidate as unwarranted. The tone of the briefing document is neutral and emphasizes short-term toxicities observed in Novartis' studies and long-term safety concerns so that the Advisory Committee will be able to conduct a thorough discussion to determine the risk/benefit ratio, Nash tells investors in a research note. Further, he believes the data from Novartis and bluebird are not an apples-to-apples comparison and reminds investors of the "differentiated safety profile" that bluebird's bb2121 has demonstrated to date. He recommends buying bluebird on the recent selloff and reiterates a Buy rating on the name with a $108 price target.
07/10/17
JEFF
07/10/17
NO CHANGE
Target $121
JEFF
Buy
Jefferies ups Kite target to $121 on 'relatively benign' FDA docs
Jefferies analyst Biren Amin raised his price target for Kite Pharma (KITE) shares to $121 from $101 after the FDA posted briefing documents ahead of the July 12 committee meeting disusing Novartis' (NVS) CAR-T therapy CTL019. The documents for the first CAR-T therapy seem "relatively benign," Amin tells investors in a research note. The FDA's view of CAR-T therapies looks in-line with expectations, but the agency may require long-term follow-up of patients to assess for risk of secondary malignancies, Amin writes. He keeps a Buy rating on Kite Pharma. The stock in late morning trading is down 3% to $102.55.

TODAY'S FREE FLY STORIES

COST

Costco

$227.35

1.68 (0.74%)

07:26
08/21/18
08/21
07:26
08/21/18
07:26
Recommendations
Costco analyst commentary  »

Costco price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Oct

LB

L Brands

$33.07

0.53 (1.63%)

07:26
08/21/18
08/21
07:26
08/21/18
07:26
Recommendations
L Brands analyst commentary  »

L Brands price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

MGM

MGM Resorts

$28.59

0.035 (0.12%)

, CZR

Caesars

$10.05

0.05 (0.50%)

07:25
08/21/18
08/21
07:25
08/21/18
07:25
Recommendations
MGM Resorts, Caesars analyst commentary  »

Room survey suggests…

MGM

MGM Resorts

$28.59

0.035 (0.12%)

CZR

Caesars

$10.05

0.05 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$225.37

2.76 (1.24%)

07:24
08/21/18
08/21
07:24
08/21/18
07:24
Initiation
Lennox initiated  »

Lennox initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

HCSG

Healthcare Services

$41.33

0.11 (0.27%)

07:23
08/21/18
08/21
07:23
08/21/18
07:23
Conference/Events
Healthcare Services management to meet with Benchmark »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 29

    Aug

GTT

GTT Communications

$38.30

-0.7 (-1.79%)

07:23
08/21/18
08/21
07:23
08/21/18
07:23
Recommendations
GTT Communications analyst commentary  »

GTT Communications should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOE

Ferro

$21.23

-0.06 (-0.28%)

07:22
08/21/18
08/21
07:22
08/21/18
07:22
Conference/Events
Ferro management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 11

    Sep

TSS

TSYS

$94.88

-0.01 (-0.01%)

07:21
08/21/18
08/21
07:21
08/21/18
07:21
Recommendations
TSYS analyst commentary  »

TSYS price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

  • 17

    Sep

  • 06

    Nov

FITB

Fifth Third

$29.83

0.145 (0.49%)

07:21
08/21/18
08/21
07:21
08/21/18
07:21
Conference/Events
Fifth Third management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 23

    Oct

YRCW

YRC Worldwide

$9.11

0.11 (1.22%)

07:21
08/21/18
08/21
07:21
08/21/18
07:21
Conference/Events
YRC Worldwide management to meet with Deutsche Bank »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 06

    Nov

MDT

Medtronic

$90.06

-0.54 (-0.60%)

07:20
08/21/18
08/21
07:20
08/21/18
07:20
Hot Stocks
Breaking Hot Stocks news story on Medtronic »

Medtronic up 4.4% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 23

    Aug

  • 05

    Sep

  • 12

    Sep

ECOM

ChannelAdvisor

$12.95

-0.15 (-1.15%)

07:20
08/21/18
08/21
07:20
08/21/18
07:20
Conference/Events
ChannelAdvisor management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 23

    Aug

  • 28

    Aug

  • 06

    Sep

  • 07

    Sep

JCI

Johnson Controls

$38.73

0.48 (1.25%)

07:20
08/21/18
08/21
07:20
08/21/18
07:20
Upgrade
Johnson Controls rating change  »

Johnson Controls upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$114.62

-0.13 (-0.11%)

07:19
08/21/18
08/21
07:19
08/21/18
07:19
Periodicals
JPMorgan to launch new investing app for free, CNBC reports »

JPMorgan has plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

  • 26

    Feb

DLB

Dolby

$68.32

-0.75 (-1.09%)

07:19
08/21/18
08/21
07:19
08/21/18
07:19
Conference/Events
Dolby management to meet with William Blair »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 28

    Aug

  • 06

    Sep

EPAM

Epam Systems

$136.36

1.355 (1.00%)

07:18
08/21/18
08/21
07:18
08/21/18
07:18
Recommendations
Epam Systems analyst commentary  »

Epam Systems price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRZO

Carrizo Oil & Gas

$22.79

0.05 (0.22%)

07:17
08/21/18
08/21
07:17
08/21/18
07:17
Conference/Events
Carrizo Oil & Gas management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

BBY

Best Buy

$79.39

0.91 (1.16%)

, AMZN

Amazon.com

$1,875.45

-6.49 (-0.34%)

07:17
08/21/18
08/21
07:17
08/21/18
07:17
Recommendations
Best Buy, Amazon.com analyst commentary  »

Best Buy valuation…

BBY

Best Buy

$79.39

0.91 (1.16%)

AMZN

Amazon.com

$1,875.45

-6.49 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 13

    Sep

ACRS

Aclaris Therapeutics

$16.01

0.34 (2.17%)

07:17
08/21/18
08/21
07:17
08/21/18
07:17
Hot Stocks
Aclaris Therapeutics announces ATI-450 findings in publication »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USB

U.S. Bancorp

$53.81

0.51 (0.96%)

07:17
08/21/18
08/21
07:17
08/21/18
07:17
Recommendations
U.S. Bancorp analyst commentary  »

U.S. Bancorp capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRON

Cronos Group

$7.33

0.78 (11.91%)

07:16
08/21/18
08/21
07:16
08/21/18
07:16
Hot Stocks
Cronos Group announces initial supply agreement for retail distribution »

Cronos Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOME

At Home Group

$34.01

0.06 (0.18%)

07:15
08/21/18
08/21
07:15
08/21/18
07:15
Recommendations
At Home Group analyst commentary  »

At Home Group's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

AZPN

Aspen Technology

$107.56

-0.21 (-0.19%)

07:15
08/21/18
08/21
07:15
08/21/18
07:15
Recommendations
Aspen Technology analyst commentary  »

Aspen Technology price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:15
08/21/18
08/21
07:15
08/21/18
07:15
General news
Treasury Market Outlook: Treasury yields are higher »

Treasury Market Outlook:…

NEO

NeoGenomics

$12.85

0.165 (1.30%)

07:15
08/21/18
08/21
07:15
08/21/18
07:15
Initiation
NeoGenomics initiated  »

NeoGenomics initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.